Hyderabad: The city-based Bharat Biotech on 21 April announced the phase 3 interim analysis results of Covaxin and said it had an efficacy of 78 per cent against mild, moderate, and severe COVID-19 cases.The second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. Due...